logo

For the Inventor, By the Inventor

Zionsville, IN, United States of America

John M Schaus

This inventor holds 101 USPTO granted patents, primarily in Pharmaceutical Compounds (CPC class 546164). Top assignees: Eli Lilly and Company, Eli Lilly Company, Eli Lilly. Active years: 1984-2015.

USPTO Granted Patents = 101

% Patents Active = 87.1

Average Co-Inventor Count = 2.8

ph-index = 15

Forward Citations = 762(Granted Patents)

Forward Citations (Not Self Cited) = 680(Dec 10, 2025)


Inventors with similar research interests:


    Location History:

    • Zionsville, IN (US) (1992 - 2013)
    • Indianapolis, IN (US) (1984 - 2015)

    Company Filing History:

    goldMedal97 out of 4,508 
     
    Eli Lilly and Company
     patents
    silverMedal2 out of 10 
     
    Eli Lilly Company
     patents
    bronzeMedal1 out of 1 
     
    Eli Lilly
     patent
    4. 1 out of 834,411 
    Other
     patents

    Years Active: 1984-2015

    Loading Chart...
    Areas of Expertise:
    CB1 Ligands
    Serotonin Receptor Modulators
    Dopamine Antagonists
    5-HT1F Agonists
    Psychotic Disorders
    Histamine H3 Antagonists
    Indole Derivatives
    Piperazine Compounds
    Aryl Alkylamines
    Diphenyl Compounds
    Tetrahydropyridines
    101 patents (USPTO):Explore Patents
    1. 8962654 - [object Object] (2015-02-24),
    2. 8420654 - 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands (2013-04-16),
    3. 8299061 - Inhibitors of diacylglycerol acyltransferase (2012-10-30),
    4. 8202873 - 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists (2012-06-19),
    5. 8168659 - 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators (2012-05-01),
    6. 8044090 - N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor (2011-10-25),
    7. 7998985 - 1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulator (2011-08-16),
    8. 7384934 - Piperazine substituted aryl benzodiazepines (2008-06-10),
    9. 7314937 - Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses (2008-01-01),
    10. 7230011 - [object Object] (2007-06-12),
    11. 7214673 - Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders (2007-05-08),
    12. 7157488 - [object Object] (2007-01-02),
    13. 6864262 - 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof (2005-03-08),
    14. 6777428 - 5-HT1f agonist (2004-08-17),
    15. 6608079 - Indole derivatives and their use as 5-HT1F agonists (2003-08-19),

    Title: The Inventor Extraordinaire: John M Schaus

    Introduction:

    John M Schaus, a brilliant inventor hailing from Zionsville, IN (US), is a pioneering figure in the field of pharmaceutical innovations. With an impressive portfolio of 101 patents to his name, Schaus continues to make significant strides in the realm of medical advancements.

    Latest Patents:

    Among his latest patents is the groundbreaking invention of 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, designed to address cognitive impairment associated with Parkinson's disease or schizophrenia. Additionally, Schaus has developed 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands, serving as CB-1 receptor inverse agonist compounds for the treatment of obesity or cognitive impairment linked to schizophrenia.

    Career Highlights:

    Schaus has made substantial contributions while working at Eli Lilly and Company, where his innovative spirit and dedication have led to significant breakthroughs in the pharmaceutical industry. His tenure at Eli Lilly Company has been marked by a commitment to excellence and a relentless pursuit of innovative solutions.

    Collaborations:

    Throughout his career, Schaus has collaborated with esteemed professionals such as Charles J Paget, Jr and Richard N Booher. These collaborations have not only enriched his work but have also paved the way for transformative inventions that promise to impact the field of medicine significantly.

    Conclusion:

    In conclusion, John M Schaus stands as a beacon of innovation, with a remarkable track record of pioneering inventions in the pharmaceutical sector. His unwavering passion for advancing medical science and improving patient outcomes underscores his status as a true visionary in the world of inventions and patents.

    Profile summary based on public USPTO records.
    Please report any incorrect information to [email protected]
    Loading…